FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically to immunology, and can be used composition for treating persistent infection, angioimmunoblastic lymphoma or nodular lymphocyte predominant Hodgkin lymphoma. Composition contains a PD-1 activity or expression inhibitor. Group of inventions also relates to a composition containing an antigen-specific T-cell, brought into contact with a compound which reduces expression or activity of PD-1.
EFFECT: using present group of inventions enables to block expression level of PD-1, which leads to increased CD8+ T-cell proliferation.
21 cl, 8 dwg, 1 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TREATMENT OF PERSISTENT INFECTIONS | 2016 |
|
RU2746383C2 |
| METHOD AND COMPOSITIONS FOR TREATMENT OF PERSISTING INFECTIONS | 2006 |
|
RU2434641C2 |
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2540490C2 |
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2478400C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| COMBINED DRUGS FOR TREATMENT OF CANCER OR INFECTION | 2016 |
|
RU2777945C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| ANTIBODIES TO PD-L1 AND THEIR APPLICATION FOR T-CELLS FUNCTION STRENGTHENING | 2009 |
|
RU2636023C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
